​

Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RCUS Stock Forecast

Arcus Biosciences stock forecast is as follows: an average price target of $31.71 (represents a 104.58% upside from RCUS’s last price of $15.50) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

RCUS Price Target

The average price target for Arcus Biosciences (RCUS) is $31.71 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $20.00. This represents a potential 104.58% upside from RCUS's last price of $15.50.

RCUS Analyst Ratings

Buy

According to 7 Wall Street analysts, Arcus Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RCUS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arcus Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Yigal NochomovitzCitigroup$46.00$17.41164.14%196.77%
Oct 21, 2024Emily BodnarH.C. Wainwright$20.00$18.448.46%29.03%
Oct 08, 2024Judah FrommerMorgan Stanley$35.00$18.0893.58%125.81%
Oct 08, 2024Eva Fortea VerdejoWells Fargo$29.00$18.0860.40%87.10%
Aug 09, 2024Jason ZemanskyBank of America Securities$23.00$13.6968.01%48.39%
Jul 08, 2024Peter LawsonBarclays$25.00$14.0078.57%61.29%
Jun 24, 2024Asthika GoonewardeneTruist Financial$44.00$16.45167.48%183.87%
Jun 04, 2024Peter LawsonBarclays$35.00$16.15116.72%125.81%
Dec 20, 2022Citigroup$42.00$20.66103.29%170.97%
Nov 23, 2022Citigroup$37.00$27.0037.04%138.71%
May 11, 2022Robert DriscollWedbush$42.00$24.0174.93%170.97%

The latest Arcus Biosciences stock forecast, released on Oct 24, 2024 by Yigal Nochomovitz from Citigroup, set a price target of $46.00, which represents a 164.14% increase from the stock price at the time of the forecast ($17.41), and a 196.77% increase from RCUS last price ($15.50).

Arcus Biosciences Price Target by Period

1M3M12M
# Anlaysts-48
Avg Price Target-$32.50$32.13
Last Closing Price$15.50$15.50$15.50
Upside/Downside-100.00%109.68%107.29%

In the current month, the average price target of Arcus Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcus Biosciences's last price of $15.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024CitigroupBuyBuyHold
Oct 21, 2024Wells FargoNeutralNeutralHold
Oct 21, 2024WedbushUnderperformUnderperformHold
Oct 21, 2024H.C. WainwrightNeutralInitialise
Oct 08, 2024Morgan StanleyUnderperformOverweightInitialise
Oct 08, 2024Wells FargoOverweightInitialise
Oct 03, 2024WedbushNeutralNeutralHold
Aug 09, 2024Bank of America SecuritiesNeutralNeutralHold
Jul 08, 2024WedbushBuyBuyHold
Jul 08, 2024CitigroupUnderperformUnderperformHold
Jul 08, 2024BarclaysOverweightOverweightHold
Jul 05, 2024Cantor FitzgeraldOverweightOverweightHold
Jun 04, 2024BarclaysOverweightOverweightHold
Jun 03, 2024CitigroupBuyBuyHold
Mar 25, 2024Robert W. BairdUnderperformUnderperformHold
Mar 25, 2024WedbushBuyBuyHold
Feb 22, 2024WedbushBuyBuyHold
Feb 22, 2024Robert W. BairdUnderperformUnderperformHold
Jan 30, 2024Morgan StanleyUnderperformUnderperformHold
Jan 30, 2024WedbushBuyBuyHold
May 26, 2023CitigroupBuyBuyHold
Dec 20, 2022CitigroupBuyBuyHold
Nov 23, 2022CitigroupBuyBuyHold

Arcus Biosciences's last stock rating was published by Citigroup on Oct 24, 2024. The company gave RCUS a "Buy" rating, the same as its previous rate.

Arcus Biosciences Financial Forecast

Arcus Biosciences Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Revenue---------------------$32.00M$29.00M$25.00M$345.00K$33.58M$26.76M$18.00M$354.50M$9.46M
Avg Forecast$283.44M$227.99M$164.52M$120.12M$65.76M$51.98M$35.43M$26.21M$25.00M$25.00M$25.00M$25.00M$38.33M$40.00M$40.00M$42.50M$29.33M$38.95M$26.24M$28.77M$28.30M$27.28M$31.81M$25.68M$23.72M$22.16M$21.57M$27.21M$11.85M$9.38M
High Forecast$371.05M$298.46M$215.37M$157.25M$86.09M$68.05M$46.38M$34.31M$32.73M$32.73M$32.73M$32.73M$50.18M$52.36M$52.36M$55.64M$32.93M$50.99M$26.24M$28.77M$34.67M$36.65M$41.65M$33.61M$31.05M$22.16M$21.57M$27.21M$11.85M$9.38M
Low Forecast$219.13M$176.26M$127.19M$92.86M$50.84M$40.18M$27.39M$20.26M$19.33M$19.33M$19.33M$19.33M$29.64M$30.92M$30.92M$32.86M$26.70M$30.11M$26.24M$28.77M$23.83M$22.50M$24.60M$19.85M$18.34M$22.16M$21.57M$27.21M$11.85M$9.38M
# Analysts111111111111111363224964374347
Surprise %---------------------1.17%0.91%0.97%0.01%1.52%1.24%0.66%29.92%1.01%

Arcus Biosciences's average Quarter revenue forecast for Dec 23 based on 4 analysts is $28.30M, with a low forecast of $23.83M, and a high forecast of $34.67M. RCUS's average Quarter revenue forecast represents a -11.56% decrease compared to the company's last Quarter revenue of $32.00M (Sep 23).

Arcus Biosciences EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111111111111111363224964374347
EBITDA---------------------$-80.00M$-83.00M$-77.00M$-66.00M$-62.82M$-64.62M$-65.14M$281.00M$-76.43M
Avg Forecast$-217.58M$-175.01M$-126.29M$-92.21M$-50.48M$-39.90M$-27.20M$-20.12M$-19.19M$-19.19M$-19.19M$-19.19M$-29.43M$-30.71M$-30.71M$-32.62M$-22.52M$-29.90M$-20.14M$-50.33M$-21.72M$-20.94M$-24.42M$-53.82M$-18.21M$-17.09M$-16.64M$-57.57M$-9.14M$-7.24M
High Forecast$-168.21M$-135.30M$-97.63M$-71.29M$-39.03M$-30.85M$-21.03M$-15.55M$-14.84M$-14.84M$-14.84M$-14.84M$-22.75M$-23.74M$-23.74M$-25.22M$-20.50M$-23.12M$-20.14M$-40.26M$-18.29M$-17.27M$-18.88M$-43.06M$-14.08M$-17.09M$-16.64M$-46.05M$-9.14M$-7.24M
Low Forecast$-284.83M$-229.11M$-165.32M$-120.71M$-66.09M$-52.23M$-35.61M$-26.33M$-25.12M$-25.12M$-25.12M$-25.12M$-38.52M$-40.20M$-40.20M$-42.71M$-25.28M$-39.14M$-20.14M$-60.39M$-26.61M$-28.13M$-31.97M$-64.59M$-23.84M$-17.09M$-16.64M$-69.08M$-9.14M$-7.24M
Surprise %---------------------3.82%3.40%1.43%3.62%3.68%3.88%1.13%-30.74%10.56%

3 analysts predict RCUS's average Quarter EBITDA for Mar 22 to be $-57.57M, with a high of $-46.05M and a low of $-69.08M. This is -120.49% lower than Arcus Biosciences's previous annual EBITDA (Dec 21) of $281.00M.

Arcus Biosciences Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111111111111111363224964374347
Net Income---------------------$-71.00M$-75.00M$-80.00M$-67.00M$-60.44M$-64.28M$-67.99M$279.37M$-77.97M
Avg Forecast$11.85M$-18.17M$-54.05M$-73.07M$-95.72M$-103.22M$-113.85M$-123.15M$-119.79M$-118.13M$-115.57M$-118.52M$-121.26M$-115.39M$-113.11M$-109.22M$-114.13M$-96.55M$-101.91M$-52.53M$-93.65M$-103.23M$-100.39M$-56.18M$1.65B$-94.60M$-85.74M$-60.09M$-99.65M$-96.31M
High Forecast$16.62M$-12.81M$-38.11M$-51.51M$-67.49M$-72.77M$-80.27M$-86.83M$-84.45M$-83.28M$-81.48M$-83.56M$-85.49M$-81.35M$-79.74M$-84.53M$-85.60M$-68.07M$-71.85M$-42.02M$-77.33M$-95.01M$-70.77M$-44.94M$1.98B$-94.60M$-85.74M$-48.07M$-99.65M$-96.31M
Low Forecast$8.36M$-25.47M$-75.78M$-102.43M$-134.19M$-144.70M$-159.60M$-172.64M$-167.92M$-165.59M$-162.01M$-166.14M$-169.98M$-161.76M$-158.56M$-133.92M$-137.75M$-135.34M$-142.86M$-63.04M$-122.86M$-112.37M$-140.72M$-67.42M$1.32B$-94.60M$-85.74M$-72.10M$-99.65M$-96.31M
Surprise %---------------------0.69%0.75%1.42%-0.04%0.64%0.75%1.13%-2.80%0.81%

Arcus Biosciences's average Quarter net income forecast for Mar 22 is $-60.09M, with a range of $-72.10M to $-48.07M. RCUS's average Quarter net income forecast represents a -121.51% decrease compared to the company's last Quarter net income of $279.37M (Dec 21).

Arcus Biosciences SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111111111111111363224964374347
SG&A---------------------$30.00M$28.00M$30.00M$28.00M$26.29M$25.84M$23.97M$23.30M$16.34M
Avg Forecast$246.38M$198.18M$143.01M$104.41M$57.16M$45.18M$30.80M$22.78M$21.73M$21.73M$21.73M$21.73M$33.32M$34.77M$34.77M$36.94M$25.50M$33.86M$22.81M$18.52M$24.60M$23.72M$27.65M$19.81M$20.62M$19.26M$18.75M$21.19M$10.30M$8.16M
High Forecast$322.54M$259.44M$187.21M$136.69M$74.83M$59.15M$40.32M$29.82M$28.45M$28.45M$28.45M$28.45M$43.62M$45.52M$45.52M$48.36M$28.62M$44.32M$22.81M$22.23M$30.14M$31.85M$36.20M$23.77M$26.99M$19.26M$18.75M$25.42M$10.30M$8.16M
Low Forecast$190.48M$153.21M$110.56M$80.72M$44.19M$34.93M$23.81M$17.61M$16.80M$16.80M$16.80M$16.80M$25.76M$26.88M$26.88M$28.56M$23.21M$26.18M$22.81M$14.82M$20.71M$19.56M$21.38M$15.85M$15.94M$19.26M$18.75M$16.95M$10.30M$8.16M
Surprise %---------------------1.26%1.01%1.51%1.36%1.37%1.38%1.13%2.26%2.00%

Arcus Biosciences's average Quarter SG&A projection for Dec 23 is $24.60M, based on 4 Wall Street analysts, with a range of $20.71M to $30.14M. The forecast indicates a -18.00% fall compared to RCUS last annual SG&A of $30.00M (Sep 23).

Arcus Biosciences EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111111111111111363224964374347
EPS---------------------$-0.95$-1.02$-1.10$-0.92$-0.84$-0.90$-0.96$3.97$-1.11
Avg Forecast$0.13$-0.20$-0.59$-0.80$-1.05$-1.13$-1.25$-1.35$-1.31$-1.29$-1.26$-1.30$-1.33$-1.26$-1.24$-1.20$-1.25$-1.06$-1.11$-1.01$-1.02$-1.13$-1.10$-1.16$-1.14$-1.04$-0.94$-0.85$-1.09$-1.06
High Forecast$0.18$-0.14$-0.42$-0.56$-0.74$-0.80$-0.88$-0.95$-0.92$-0.91$-0.89$-0.91$-0.94$-0.89$-0.87$-0.92$-0.94$-0.74$-0.79$-0.71$-0.85$-1.04$-0.77$-0.82$-0.80$-1.04$-0.94$-0.85$-1.09$-1.06
Low Forecast$0.09$-0.28$-0.83$-1.12$-1.47$-1.58$-1.75$-1.89$-1.84$-1.81$-1.77$-1.82$-1.86$-1.77$-1.73$-1.47$-1.51$-1.48$-1.56$-1.42$-1.34$-1.23$-1.54$-1.63$-1.60$-1.04$-0.94$-0.85$-1.09$-1.06
Surprise %---------------------0.84%0.93%0.95%0.81%0.81%0.96%1.12%-3.63%1.05%

According to 3 Wall Street analysts, Arcus Biosciences's projected average Quarter EPS for Mar 22 is $-0.85, with a low estimate of $-0.85 and a high estimate of $-0.85. This represents a -121.52% decrease compared to RCUS previous annual EPS of $3.97 (Dec 21).

Arcus Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
CNSPCNS Pharmaceuticals$0.11$0.50354.55%
ITOSiTeos Therapeutics$7.69$33.50335.63%Buy
TCRXTScan Therapeutics$2.97$12.00304.04%Buy
RLAYRelay Therapeutics$4.50$18.00300.00%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
GPCRStructure Therapeutics$31.48$99.00214.49%Buy
IMMXImmix Biopharma$2.29$7.00205.68%Buy
CGEMCullinan Oncology$11.49$34.00195.91%Buy
ANNXAnnexon$4.88$14.00186.89%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
RCUSArcus Biosciences$16.08$31.7197.20%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold

RCUS Forecast FAQ

Is Arcus Biosciences a good buy?

Yes, according to 7 Wall Street analysts, Arcus Biosciences (RCUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of RCUS's total ratings.

What is RCUS's price target?

Arcus Biosciences (RCUS) average price target is $31.71 with a range of $20 to $46, implying a 104.58% from its last price of $15.5. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arcus Biosciences stock go up soon?

According to Wall Street analysts' prediction for RCUS stock, the company can go up by 104.58% (from the last price of $15.5 to the average price target of $31.71), up by 196.77% based on the highest stock price target, and up by 29.03% based on the lowest stock price target.

Can Arcus Biosciences stock reach $20?

RCUS's average twelve months analyst stock price target of $31.71 supports the claim that Arcus Biosciences can reach $20 in the near future.

What are Arcus Biosciences's analysts' financial forecasts?

Arcus Biosciences's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $179.38M (high $234.83M, low $138.68M), average EBITDA is $-138M (high $-106M, low $-180M), average net income is $-436M (high $-307M, low $-611M), average SG&A $155.93M (high $204.13M, low $120.55M), and average EPS is $-4.77 (high $-3.363, low $-6.686). RCUS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $796.07M (high $1.04B, low $615.44M), average EBITDA is $-611M (high $-472M, low $-800M), average net income is $-133M (high $-85.815M, low $-195M), average SG&A $691.98M (high $905.88M, low $534.97M), and average EPS is $-1.46 (high $-0.939, low $-2.137).

Did the RCUS's actual financial results beat the analysts' financial forecasts?

Based on Arcus Biosciences's last annual report (Dec 2022), the company's revenue was $112M, beating the average analysts forecast of $94.66M by 18.32%. Apple's EBITDA was $-264M, beating the average prediction of $-110M by 141.09%. The company's net income was $-267M, missing the average estimation of $1.41B by -118.96%. Apple's SG&A was $104M, beating the average forecast of $79.82M by 30.30%. Lastly, the company's EPS was $-4.87, beating the average prediction of $-3.973 by 22.57%. In terms of the last quarterly report (Sep 2023), Arcus Biosciences's revenue was $32M, beating the average analysts' forecast of $27.28M by 17.28%. The company's EBITDA was $-80M, beating the average prediction of $-20.944M by 281.97%. Arcus Biosciences's net income was $-71M, missing the average estimation of $-103M by -31.22%. The company's SG&A was $30M, beating the average forecast of $23.72M by 26.49%. Lastly, the company's EPS was $-0.95, missing the average prediction of $-1.129 by -15.89%